Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTRN | P46939 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 9/20 | 0.54 |
| ▸ | RAB9A | P51151 | 8/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 3/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | HPGD | P15428 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15844590 | 0.90 | UTRN (0.56) | UTRNNPC1RAB9APOLBDYRK1A | |
| SCHEMBL4052930 | 0.84 | ESR1 (0.57) | UTRNNPC1RAB9ACYP1A2ESR1 | |
| SCHEMBL15844951 | 0.84 | NPC1 (0.63) | UTRNNPC1RAB9APOLBDYRK1A | |
| SCHEMBL23387567 | 0.80 | NPC1 (0.59) | NPC1RAB9AESR1ESR2SMN1; SMN2 | |
| SCHEMBL4060159 | 0.79 | UTRN (0.52) | UTRNNPC1RAB9APOLBDYRK1A | |
| SCHEMBL4059650 | 0.78 | VSIR (0.54) | UTRNNPC1RAB9APOLBDYRK1A | |
| SCHEMBL25498956 | 0.78 | NPC1 (0.55) | NPC1RAB9APOLBESR1ESR2 | |
| SCHEMBL15845073 | 0.78 | RAB9A (0.58) | UTRNNPC1RAB9APOLBDYRK1A | |
| SCHEMBL2139699 | 0.77 | SMN1; SMN2 (0.57) | NPC1RAB9APOLBESR1ESR2 | |
| SCHEMBL9274000 | 0.77 | NPC1 (0.78) | NPC1RAB9APOLBDYRK1ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9246108-B2 | Quinoline-benzoxazole derived compounds for electronic films and devices | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-01-26 | — | — | US | disclosed |
| US-9246108-B2 | Quinoline-benzoxazole derived compounds for electronic films and devices | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-01-26 | — | — | US | disclosed |
| US-20140183413-A1 | QUINOLINE-BENZOXAZOLE DERIVED COMPOUNDS FOR ELECTRONIC FILMS AND DEVICES | DOW GLOBAL TECHNOLOGIES LLC (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140183413-A1 | QUINOLINE-BENZOXAZOLE DERIVED COMPOUNDS FOR ELECTRONIC FILMS AND DEVICES | DOW GLOBAL TECHNOLOGIES LLC (US) | 2014-07-03 | — | — | US | disclosed |
| US-7622479-B2 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-7622479-B2 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-7622479-B2 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20050101647-A1 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1460067-A1 | BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101647-A1 | Bicyclic derivative, its production and use | ABL1, SRC, PTK2B | UTRN 4874/4885NPC1 4740/4885RAB9A 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.